Publications
282 results found
Boettcher A, Zarucha A, Koebe T, et al., 2022, Musical Activity During Life Is Associated With Multi-Domain Cognitive and Brain Benefits in Older Adults, FRONTIERS IN PSYCHOLOGY, Vol: 13, ISSN: 1664-1078
- Author Web Link
- Cite
- Citations: 3
Kalman JL, Burkhardt G, Adorjan K, et al., 2022, Biobanking in everyday clinical practice in psychiatry-The Munich Mental Health Biobank, FRONTIERS IN PSYCHIATRY, Vol: 13, ISSN: 1664-0640
- Author Web Link
- Cite
- Citations: 1
Sadlon A, Takousis P, Evangelou E, et al., 2022, A multi-omics approach identifies a blood-based miRNA signature of cognitive decline in two large observational trials
<jats:title>Abstract</jats:title><jats:p>Identifying individuals before the onset of overt symptoms is a key prerequisite for the prevention of Alzheimer’s disease (AD). A wealth of data reports dysregulated microRNA (miRNA) expression in the blood of individuals with AD, but evidence in individuals at subclinical stages is sparse. In this study, a qPCR analysis of a prioritised set of 38 candidate miRNAs in the blood of 830 healthy individuals from the CHARIOT PRO cohort (West London, UK) was undertaken. Here, we identified six differentially expressed miRNAs (hsa-miR-128-3p, hsa-miR-144-5p, hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-29c-3p and hsa-miR-363-3p) in the blood of individuals with low cognitive performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A pathway enrichment analysis for the six miRNAs indicated involvement of apoptosis and inflammation, relevant in early AD stages. Subsequently, we used whole genome sequencing (WGS) data from 750 individuals from the AD Neuroimaging Initiative (ADNI) to perform a genetic association analysis for polymorphisms within the significant miRNAs’ genes and CSF concentrations of phosphorylated-tau, total-tau, amyloid-β42 and soluble-TREM2 and BACE1 activity. Our analysis revealed 24 SNPs within<jats:italic>MIR29C</jats:italic>to be associated with CSF levels of amyloid-β42 and soluble-TREM2 and BACE1 activity. Our study shows the potential of a six-miRNA set as diagnostic blood biomarker of subclinical cognitive deficits in AD. Polymorphisms within<jats:italic>MIR29C</jats:italic>suggest a possible interplay between the amyloid cascade and microglial activation at preclinical stages of AD.</jats:p>
Zatcepin A, Xiang X, Parhizkar S, et al., 2022, Regional Desynchronization of Microglial Activity is Associated with Cognitive Decline in Alzheimer's Disease, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
Perna L, Trares K, Perneczky R, et al., 2022, Risk of Late-Onset Depression and Cognitive Decline: Results From Inflammatory Proteome Analyses in a Prospective Population-Based Cohort Study, AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, Vol: 30, Pages: 689-700, ISSN: 1064-7481
- Author Web Link
- Cite
- Citations: 4
Rullmann M, Brendel M, Rumpf J, et al., 2022, In vivo staging of tau pathology in progressive supranuclear palsy with multicenter F-18-PI-2620 PET, 30th International Symposium on Cerebral Blood Flow, Metabolism and Function (BRAIN) in conjunction with the 15th International Conference on Quantification of Brain Function with PET (BRAIN PET), Publisher: SAGE PUBLICATIONS INC, Pages: 12-13, ISSN: 0271-678X
Jessen F, Wolfsgruber S, Kleineindam L, et al., 2022, Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers, ALZHEIMERS & DEMENTIA, ISSN: 1552-5260
- Author Web Link
- Cite
- Citations: 13
Tato M, Perneczky R, 2022, Diagnosing Alzheimer's dementia - a playground for academics or a sensible clinical measure?, DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, Vol: 147, Pages: 564-569, ISSN: 0012-0472
Livingston NR, Calsolaro V, Hinz R, et al., 2022, Relationship between astrocyte reactivity, using novel <SUP>11</SUP>C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals, MOLECULAR PSYCHIATRY, Vol: 27, Pages: 2019-2029, ISSN: 1359-4184
- Author Web Link
- Cite
- Citations: 13
Kurz C, Walker L, Rauchmann B-S, et al., 2022, Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies, NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol: 48, ISSN: 0305-1846
- Author Web Link
- Cite
- Citations: 30
Brosseron F, Maass A, Kleineidam L, et al., 2022, Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease, NEURON, Vol: 110, Pages: 1009-+, ISSN: 0896-6273
- Author Web Link
- Cite
- Citations: 10
Franzmeier N, Brendel M, Beyer L, et al., 2022, Tau deposition patterns are associated with functional connectivity in primary tauopathies, NATURE COMMUNICATIONS, Vol: 13
- Author Web Link
- Cite
- Citations: 21
Rullmann M, Brendel M, Schroeter ML, et al., 2022, Multicenter <SUP>18</SUP>F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease, Publisher: MDPI, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 7
Ersoezlue E, Rauchmann B-S, Schneider-Axmann T, et al., 2022, Lifelong experiences as a proxy of cognitive reserve moderate the association between connectivity and cognition in Alzheimer's disease, NEUROBIOLOGY OF AGING, Vol: 122, Pages: 33-44, ISSN: 0197-4580
- Author Web Link
- Cite
- Citations: 2
Schuster S, Beyer L, Palleis C, et al., 2022, Impact of Partial Volume Correction on [<SUP>18</SUP>F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome, BRAIN SCIENCES, Vol: 12
Alexopoulos P, Frounta M, Perneczky R, 2022, The multidimensional beneficial effect of physical exercise on symptoms of neurocognitive disorder, INTERNATIONAL PSYCHOGERIATRICS, Vol: 34, Pages: 109-112, ISSN: 1041-6102
Ersoezlue E, Perneczky R, Tatò M, et al., 2022, A residual marker of cognitive reserve is associated with resting-state intrinsic functional connectivity along the Alzheimer’s disease continuum
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Cognitive reserve (CR) explains interindividual differences in the impact of neurodegenerative burden on cognitive and daily functioning. A residual model was proposed to estimate CR more accurately compared to static measures, such as years of education. However, the functional brain correlates of residual CR markers (CRM) remain unexplored.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>From the DELCODE cohort, 318 participants with resting-state functional and structural MRI data were included and stratified using cerebrospinal fluid (CSF) biomarkers according to the A(myloid-β, Aβ)/T(au)/N(eurodegeneration) classification scheme, resulting in 112 Aβ-negative healthy controls and 206 Aβ-positive patients in the Alzheimer’s disease (AD) spectrum.. CRM was calculated utilizing residuals obtained from a multilinear regression model using global cognition as dependent variable and demographic and disease burden measures as predictors. Associations between the CRM and intrinsic network connectivity (INC) in resting-state networks associated with cognition were explored, including the default mode network (DMN), frontoparietal network (FPN), salience network (SAL) and dorsal attention network (DAN). Moreover, the association between memory performance-associated regional INC and CRM was assessed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>CRM was positively associated with INC in the DMN in the entire cohort. In a subgroup analysis, the A+T+N+ group revealed an anti-correlation between SAL and DMN. Furthermore, CRM was positively associated with the anti-correlation between the memory-related regions in the FPN and the DMN in the A+ and A+T/N+ subgroups.</jats:p></jats:sec><jats:sec><j
Wolfsgruber S, Kleineidam L, Weyrauch A-S, et al., 2022, Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease, JOURNAL OF ALZHEIMERS DISEASE, Vol: 87, Pages: 545-555, ISSN: 1387-2877
- Author Web Link
- Cite
- Citations: 4
Kolabas ZI, Kuemmerle LB, Perneczky R, et al., 2021, Multi-omics and 3D-imaging reveal bone heterogeneity and unique calvaria cells in neuroinflammation
<jats:title>SUMMARY</jats:title><jats:p>The meninges of the brain are an important component of neuroinflammatory response. Diverse immune cells move from the calvaria marrow into the dura mater via recently discovered skull-meninges connections (SMCs). However, how the calvaria bone marrow is different from the other bones and whether and how it contributes to human diseases remain unknown. Using multi-omics approaches and whole mouse transparency we reveal that bone marrow cells are highly heterogeneous across the mouse body. The calvaria harbors the most distinct molecular signature with hundreds of differentially expressed genes and proteins. Acute brain injury induces skull-specific alterations including increased calvaria cell numbers. Moreover, TSPO-positron-emission-tomography imaging of stroke, multiple sclerosis and neurodegenerative disease patients demonstrate disease-associated uptake patterns in the human skull, mirroring the underlying brain inflammation. Our study indicates that the calvaria is more than a physical barrier, and its immune cells may present new ways to control brain pathologies.</jats:p><jats:sec><jats:title>Graphical Abstract</jats:title><jats:fig id="ufig1" position="float" fig-type="figure" orientation="portrait"><jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="473988v1_ufig1" position="float" orientation="portrait" /></jats:fig></jats:sec><jats:sec><jats:title>Highlights</jats:title><jats:list list-type="order"><jats:list-item><jats:p>Bone marrow across the mouse body display heterogeneity in their molecular profile</jats:p></jats:list-item><jats:list-item><jats:p>Calvaria cells have a distinct profile that is relevant to brain pathologies</jats:p></jats:list-item><jats:list-item>&
Rauchmann BS, Schneider-Axmann T, Perneczky R, 2021, Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 92, Pages: 1289-1295, ISSN: 0022-3050
- Author Web Link
- Cite
- Citations: 22
Dyrba M, Hanzig M, Altenstein S, et al., 2021, Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease, ALZHEIMERS RESEARCH & THERAPY, Vol: 13
- Author Web Link
- Cite
- Citations: 15
Islam MR, Kaurani L, Berulava T, et al., 2021, A microRNA signature that correlates with cognition and is a target against cognitive decline, EMBO MOLECULAR MEDICINE, Vol: 13, ISSN: 1757-4676
- Author Web Link
- Cite
- Citations: 19
Song M, Scheifele M, Barthel H, et al., 2021, Feasibility of short imaging protocols for [<SUP>18</SUP>F]PI-2620 tau-PET in progressive supranuclear palsy, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 48, Pages: 3872-3885, ISSN: 1619-7070
- Author Web Link
- Cite
- Citations: 12
Xiang X, Wind K, Wiedemann T, et al., 2021, Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases, SCIENCE TRANSLATIONAL MEDICINE, Vol: 13, ISSN: 1946-6234
- Author Web Link
- Cite
- Citations: 65
Rullmann M, Brendel M, Schroeter ML, et al., 2021, In vivo Braak staging of tau pathology in Alzheimer's disease: A multicenter [18F]PI-2620 PET study, Publisher: SPRINGER, Pages: S172-S173, ISSN: 1619-7070
Palleis C, Brendel M, Finze A, et al., 2021, Cortical [<SUP>18</SUP>F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes, MOVEMENT DISORDERS, Vol: 36, Pages: 2104-2115, ISSN: 0885-3185
- Author Web Link
- Cite
- Citations: 31
Calsolaro V, Matthews PM, Donat CK, et al., 2021, Astrocyte reactivity with late onset cognitive impairment assessed in-vivo using 11C-BU99008 PET and its relationship with amyloid load, Molecular Psychiatry, Vol: 26, Pages: 5848-5855, ISSN: 1359-4184
11C-BU99008 is a novel positron emission tomography (PET) tracer that enables selective imaging of astrocyte reactivity in vivo. To explore astrocyte reactivity associated with Alzheimer’s disease, 11 older, cognitively impaired (CI) subjects and 9 age-matched healthy controls (HC) underwent 3T magnetic resonance imaging (MRI), 18F-florbetaben and 11C-BU99008 PET. The 8 amyloid (Aβ)-positive CI subjects had higher 11C-BU99008 uptake relative to HC across the whole brain, but particularly in frontal, temporal, medial temporal and occipital lobes. Biological parametric mapping demonstrated a positive voxel-wise neuroanatomical correlation between 11C-BU99008 and 18F-florbetaben. Autoradiography using 3H-BU99008 with post-mortem Alzheimer’s brains confirmed through visual assessment that increased 3H-BU99008 binding localised with the astrocyte protein glial fibrillary acid protein and was not displaced by PiB or florbetaben. This proof-of-concept study provides direct evidence that 11C-BU99008 can measure in vivo astrocyte reactivity in people with late-life cognitive impairment and Alzheimer’s disease. Our results confirm that increased astrocyte reactivity is found particularly in cortical regions with high Aβ load. Future studies now can explore how clinical expression of disease varies with astrocyte reactivity.
Udeh-Momoh CT, Watermeyer T, Price G, et al., 2021, Protocol of the cognitive health in ageing register: investigational, observational and trial studies in dementia research (CHARIOT): prospective readiness cOhort (PRO) SubStudy., BMJ Open, Vol: 11, Pages: 1-12, ISSN: 2044-6055
INTRODUCTION: The Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy (CPSS), sponsored by Janssen Pharmaceutical Research & Development LLC, is an Alzheimer's disease (AD) biomarker enriched observational study that began 3 July 2015 CPSS aims to identify and validate determinants of AD, alongside cognitive, functional and biological changes in older adults with or without detectable evidence of AD pathology at baseline. METHODS AND ANALYSIS: CPSS is a dual-site longitudinal cohort (3.5 years) assessed quarterly. Cognitively normal participants (60-85 years) were recruited across Greater London and Edinburgh. Participants are classified as high, medium (amnestic or non-amnestic) or low risk for developing mild cognitive impairment-Alzheimer's disease based on their Repeatable Battery for the Assessment of Neuropsychological Status performance at screening. Additional AD-related assessments include: a novel cognitive composite, the Global Preclinical Alzheimer's Cognitive Composite, brain MRI and positron emission tomography and cerebrospinal fluid analysis. Lifestyle, other cognitive and functional data, as well as biosamples (blood, urine, and saliva) are collected. Primarily, study analyses will evaluate longitudinal change in cognitive and functional outcomes. Annual interim analyses for descriptive data occur throughout the course of the study, although inferential statistics are conducted as required. ETHICS AND DISSEMINATION: CPSS received ethical approvals from the London-Central Research Ethics Committee (15/LO/0711) and the Administration of Radioactive Substances Advisory Committee (RPC 630/3764/33110) The study is at the forefront of global AD prevention efforts, with frequent and robust sampling of the well-characterised cohort, allowing for detection of incipient pathophysiological, cognitive and functional changes that could inform therape
Ballarini T, van Lent DM, Brunner J, et al., 2021, Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age, NEUROLOGY, Vol: 96, Pages: E2920-E2932, ISSN: 0028-3878
Vettermann FJ, Harris S, Schmitt J, et al., 2021, Impact of TSPO Receptor Polymorphism on [<SUP>18</SUP>F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders, LIFE-BASEL, Vol: 11
- Author Web Link
- Cite
- Citations: 13
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.